{"filing":{"accession_number":"0000318154-26-000124","cik":"0000318154","ticker":"AMGN","company_name":"AMGEN INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"amgn-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000124/amgn-20260804.htm"},"events":[{"id":23783,"run_id":21510,"accession_number":"0000318154-26-000124","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"summary":"This is a clear earnings release disclosing Amgen's unaudited financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenues of $10.1 billion (up 10% YoY), GAAP EPS of $4.37 (up 65%), and non-GAAP EPS of $6.29 (up 4%). The filing explicitly states \"On August 4, 2026, the Company issued a press release announcing its unaudited results of operations\" and includes detailed product sales performance, operating expense analysis, cash flow metrics, and 2026 guidance. This is a material quarterly earnings disclosure typical of Item 2.02.","company_name":"AMGEN INC","ticker":"AMGN","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24112,"accession_number":"0000318154-26-000124","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"This is a clear earnings release disclosing Amgen's unaudited financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenues of $10.1 billion (up 10% YoY), GAAP EPS of $4.37 (up 65%), and non-GAAP EPS of $6.29 (up 4%). The filing explicitly states \"On August 4, 2026, the Company issued a press release announcing its unaudited results of operations\" and includes detailed product sales performance, operating expense analysis, cash flow metrics, and 2026 guidance. This is a material quarterly earnings disclosure typical of Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:16:44.677197+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24112,"accession_number":"0000318154-26-000124","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"This is a clear earnings release disclosing Amgen's unaudited financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenues of $10.1 billion (up 10% YoY), GAAP EPS of $4.37 (up 65%), and non-GAAP EPS of $6.29 (up 4%). The filing explicitly states \"On August 4, 2026, the Company issued a press release announcing its unaudited results of operations\" and includes detailed product sales performance, operating expense analysis, cash flow metrics, and 2026 guidance. This is a material quarterly earnings disclosure typical of Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:16:44.677197+00:00","company_name":"AMGEN INC","ticker":"AMGN","filing_date":"2026-08-04"}]}